Q-omics provides the consensus-scored PSAT1 profile across patient tissues and cancer cell-line models. PSAT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSAT1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PSAT1 RNA expression shows 25,514 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where PSAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSAT1 survival associations across molecular data types. PSAT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSAT1 RNA expression–survival associations across cancer types. High PSAT1 expression shows unfavorable associations in KIRC, MESO, KICH, KIRP, UVM and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSAT1 RNA expression.
This table summarizes PSAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSAT1 shows lower tumor expression in KIRC and higher tumor expression in COAD, LUAD, LUSC, BLCA and HNSC. The COAD box plot shows higher PSAT1 RNA expression in tumor versus normal tissue (log2 FC = +3.402, t-test p < 0.001).
This table shows molecular features associated with PSAT1 in patient tissues and cancer cell lines. In patient samples, PSAT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
